摘要
目的 评价胺碘酮和索他洛尔治疗心房颤动（房颤）的有效性和安全性.方法 计算机检索Cochrane图书馆、PubMed、EMBASE、CBM、CNKI、VIP等数据库,并辅以Google Scholar等检索,收集有关胺碘酮和索他洛尔对比治疗房颤的随机对照试验（RCT）,由2名参与者独立评价纳入研究质量、提取资料,对两药房颤转复率、复发率及不良反应采用RevMan 5.0软件进行Meta分析.结果 共纳入14个RCT（1 508例患者）;Meta分析结果显示胺碘酮与索他洛尔房颤转复率及不良反应无统计学差异,胺碘酮防止房颤复发作用优于索他洛尔（比数比=0.49,95%可信区间为0.31～0.75,P=0.001）.结论 胺碘酮与索他洛尔在小剂量范围内均较为安全,前者降低房颤复发率效果较好.
Objective To evaluate the effectiveness and security of using amiedarane versus sotalol for the treatement of atrial fibrillationg（AF）. Methods Randomized controlled trims （RCT） were searched and identified from the Cochrane Library,PubMed,EMBASE, CBM, CNKI and VIP, and Google Scholar retrieval was used as the assistance. Quality assess- ment and data extraction were done by two reviewers independently, Meta-analyses were performed on the the AF recur- rence rate, conversion rate and adverse events by RevMan 5.0. Results Fourteen RCT （ involving 1 508 patients） were identified;the results of Meta-analysis showed that there were no significant difference in the conversion rate and adverse e- vents of amiedarane and sotalol, but the amiodarane decreased the risk of AF recurrence （ OR = 0.49,95% CI was 0.31- 0.75） ,P = 0. 001）. Conclusion Small dose of amiodarone and so＇talol are both safety , the former has the superiority to decrease the recurrence rate of AF.
出处
《山东医药》
CAS
北大核心
2010年第23期4-6,共3页
Shandong Medical Journal
基金
兰州大学"循证医学创新项目"(2009LDEBM-A)
